- First dosing of AD-214 achieved in Phase I extension study
- On track to obtain interim results in 2023, full results in Q1 2024
- Will generate valuable data to inform and de-risk the Phase II study design
- Ongoing discussions confirm value of study for potential partners
MELBOURNE Australia, 4 August 2023: AdAlta Limited (ASX:1AD), the clinical stage drug discovery company developing novel therapeutic products using its i-body platform provides an update on its lead fibrosis asset, AD-214. The first participants in the Company’s Phase I extension study of AD-214 have successfully received their first dose.
The Phase I extension study, titled “Safety, Tolerability, PK and PD Study of AD-214 Administered to Healthy Volunteers and Patients with Interstitial Lung Disease or Chronic Kidney Disease”, aims to confirm safety and pharmacokinetic and pharmacodynamic profile of multiple doses of AD-214, using higher doses than in the previous Phase I study. Commencing this study returns AD-214 to the clinic more than a year earlier than forecast in 2022. The new clinical data is crucial as it will better inform the safety profile and target dosing schedule of AD-214 for future Phase II studies and will also strengthen partnering initiatives.
AdAlta CEO and Managing Director, Dr Tim Oldham commented, “We extend our gratitude to the volunteers who are participating in this extension study. Their involvement is essential in advancing a potential new therapy for sufferers of debilitating and incurable idiopathic pulmonary fibrosis and other fibrotic diseases. The Company’s meetings with potential partners continue to indicate that this study will materially enhance the attractiveness of AD-‑214 to partners.”
The study is initially enrolling up to 8 healthy volunteers, six participants to receive AD-214 and two participants placebo. The first, or sentinel, group of two participants has now received the first of four 10 mg/kg doses of AD-214 or placebo with no issues reported. AdAlta continues to anticipate interim results before the end of 2023, with final assessment visits to be completed and full results expected to be available in the first quarter of 2024.
Details of the study can be found at: www.clinicaltrials.gov/study/NCT05914909
Authorised for lodgement by:
CEO and Managing Director
 ASX Announcement, 28 April 2023, 29 June 2023
AdAlta Limited is a clinical stage drug development company headquartered in Melbourne, Australia. The Company is using its proprietary i-body technology platform to solve challenging drug targeting problems and generate a promising new class of single domain antibody protein therapeutics with the potential to treat some of today’s most challenging medical conditions.
The i-body technology mimics the shape and stability of a unique and versatile antigen binding domain that was discovered initially in sharks and then developed as a human protein. The result is a range of unique proteins capable of interacting with high selectivity, specificity and affinity with previously difficult to access targets such as G-protein coupled receptors (GPCRs) that are implicated in many serious diseases. i-bodies are the first fully human single domain antibody scaffold and the first based on the shark motif to reach clinical trials.
AdAlta is extending Phase I clinical studies for its lead i-body candidate, AD-214, that is being developed for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases for which current therapies are sub-optimal and there is a high unmet medical need. Preparation for Phase II clinical studies is also underway. AdAlta has a second target in discovery research, also in the field of fibrosis and inflammation.
The Company is also entering collaborative partnerships to advance the development of its i-body platform. It has a collaboration with Carina Biotech to co-develop precision engineered, i-body enabled CAR-T cell therapies (i-CAR-T) to bring new hope to patients with cancer. It has an agreement with GE Healthcare to co-develop i-bodies as diagnostic imaging agents (i-PET imaging) against Granzyme B, a biomarker of response to immuno-oncology drugs, a program now in pre-clinical development.
AdAlta’s strategy is to maximise the products developed using its next generation i-body platform by internally discovering and developing selected i-body enabled product candidates against GPCRs implicated in fibrosis, inflammation and cancer and partnering with other biopharmaceutical companies to develop product candidates against other classes of receptor, in other indications, and in other product formats.
Further information can be found at: https://adalta.com.au
For more information, please contact:
Tim Oldham, CEO & Managing Director
Tel: +61 403 446 665
Tel: +61 411 117 774
Founded in 2009, EmergingGrowth.com quickly became a leading independent small cap media portal. Over the years, it has developed an extensive history of providing unparalleled content, in identifying emerging growth companies and markets that can be overlooked by the investment community.
The next step in its evolution is the Emerging Growth Conference.
About the Emerging Growth Conference
The Emerging Growth conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the investment community from the convenience of their office, in an effective and time efficient manner.
The audience includes potentially tens of thousands of Individual and Institutional investors, as well as Investment advisors and analysts.
All Conferences are first announced on Twitter – Follow us on Twitter
All Conference replays emerge on our YouTube Channel – Subscribe to our YouTube Channel
All sessions are conducted through video webcasts and will take place in the Eastern time zone. Our conference serves as a vehicle for Emerging Growth to build relationships with our existing and potential clients. Accordingly, a certain number of the presenting companies are our current clients, and some may become our clients in the future. In exchange for services we provide, our clients pay us fees in the form of cash and securities, and we may currently have, or in the future may have investments in the securities of certain of the presenting companies. Finally, certain of the presenting companies have paid us a fee to secure a presentation time slot or to present generally. The presentations to be delivered by the presenting companies (including any handouts of written materials) have not been approved, endorsed by or otherwise reviewed by EmergingGrowth.com nor should they in any way be construed to have been made in connection with an offer to sell or a solicitation of an offer to buy securities. Please consult an investment professional before investing in anything viewed on the Emerging Growth Conference or on EmergingGrowth.com.
If you believe your company, product or service is at the cusp of going mainstream, or you have an idea for an “Emerging Growth” company that might fit our model, contact us here.